DDInter624 DDInter425
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Aminoglutethimide
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Aminoglutethimide
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound) and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efavirenz (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Aminoglutethimide (Compound) and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efavirenz (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efavirenz (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Cobimetinib
Efavirenz (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Cobimetinib